(UTHR) United Therapeutics - Ratings and Ratios
Treprostinil, Treprostinil, Treprostinil, Tadalafil, Dinutuximab
Dividends
Currently no dividends paid| Risk via 10d forecast | |
|---|---|
| Volatility | 32.4% |
| Value at Risk 5%th | 44.3% |
| Relative Tail Risk | -16.93% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.72 |
| Alpha | 22.62 |
| CAGR/Max DD | 0.63 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.392 |
| Beta | 0.421 |
| Beta Downside | 0.608 |
| Drawdowns 3y | |
|---|---|
| Max DD | 33.00% |
| Mean DD | 13.78% |
| Median DD | 15.05% |
Description: UTHR United Therapeutics October 16, 2025
United Therapeutics (NASDAQ: UTHR) is a U.S.-based biotech that focuses on products for chronic, life-threatening conditions, chiefly pulmonary arterial hypertension (PAH) and high-risk neuroblastoma. Its current commercial portfolio includes inhaled Tyvaso (dry-powder and solution), the treprostinil injection Remodulin, the oral tablet Orenitram, the PDE-5 inhibitor Adcirca, and the monoclonal antibody Unituxin for neuroblastoma, plus the Remunity infusion pump.
The pipeline extends beyond the core PAH franchise: RemoPro (an oral treprostinil), the selective prostacyclin receptor agonist Ralinepag (in partnership with Arena Pharmaceuticals), Aurora-GT gene-therapy for vascular remodeling, nebulized Tyvaso for idiopathic pulmonary fibrosis, and early-stage xenograft organ products. Strategic collaborations with DEKA (sub-cutaneous delivery system), MannKind (inhalation powder and Dreamboat device), and Arena broaden both development capacity and commercialization reach.
Key financial and market metrics (FY 2023): revenue of $2.0 billion, driven > 70 % by PAH products; cash and short-term investments of $1.3 billion, providing a runway of ≈ 3 years at current burn; and a net loss of $140 million, reflecting heavy R&D spend. The global PAH market is projected to grow at a CAGR of ~6 % to exceed $5 billion by 2028, while the neuroblastoma segment benefits from increasing pediatric oncology funding and favorable reimbursement trends.
Given the company’s cash position, pipeline diversification, and exposure to a growing specialty-therapy market, analysts should monitor FDA decision dates for RemoPro and Aurora-GT, as well as the commercial uptake of the inhaled Tyvaso DPI, which could materially shift revenue mix.
For a deeper quantitative assessment of UTHR’s valuation metrics, you may find ValueRay’s analyst toolkit useful.
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (1.27b TTM) > 0 and > 6% of Revenue (6% = 187.7m TTM) |
| FCFTA 0.15 (>2.0%) and ΔFCFTA 2.65pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 94.22% (prev 113.5%; Δ -19.23pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.21 (>3.0%) and CFO 1.56b > Net Income 1.27b (YES >=105%, WARN >=100%) |
| Net Debt (-1.14b) to EBITDA (1.71b) ratio: -0.67 <= 3.0 (WARN <= 3.5) |
| Current Ratio 6.40 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (47.3m) change vs 12m ago -2.27% (target <= -2.0% for YES) |
| Gross Margin 88.59% (prev 88.94%; Δ -0.35pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 43.23% (prev 38.69%; Δ 4.53pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 69.07 (EBITDA TTM 1.71b / Interest Expense TTM 24.3m) >= 6 (WARN >= 3) |
Altman Z'' 19.13
| (A) 0.40 = (Total Current Assets 3.49b - Total Current Liabilities 546.3m) / Total Assets 7.35b |
| (B) 1.11 = Retained Earnings (Balance) 8.19b / Total Assets 7.35b |
| warn (B) unusual magnitude: 1.11 — check mapping/units |
| (C) 0.23 = EBIT TTM 1.68b / Avg Total Assets 7.24b |
| (D) 10.77 = Book Value of Equity 8.19b / Total Liabilities 760.9m |
| Total Rating: 19.13 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 92.08
| 1. Piotroski 6.50pt |
| 2. FCF Yield 5.88% |
| 3. FCF Margin 35.86% |
| 4. Debt/Equity 0.05 |
| 5. Debt/Ebitda -0.67 |
| 6. ROIC - WACC (= 11.39)% |
| 7. RoE 18.83% |
| 8. Rev. Trend 98.07% |
| 9. EPS Trend 74.34% |
What is the price of UTHR shares?
Over the past week, the price has changed by +0.81%, over one month by +6.81%, over three months by +22.28% and over the past year by +33.85%.
Is UTHR a buy, sell or hold?
- Strong Buy: 6
- Buy: 2
- Hold: 6
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the UTHR price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 518.3 | 6.9% |
| Analysts Target Price | 518.3 | 6.9% |
| ValueRay Target Price | 569.2 | 17.4% |
UTHR Fundamental Data Overview December 11, 2025
P/E Trailing = 18.0645
P/E Forward = 15.4083
P/S = 6.8866
P/B = 3.1328
P/EG = 1.4347
Beta = 0.861
Revenue TTM = 3.13b USD
EBIT TTM = 1.68b USD
EBITDA TTM = 1.71b USD
Long Term Debt = unknown (none)
Short Term Debt = 300.0m USD (from shortTermDebt, last fiscal year)
Debt = 300.0m USD (from shortLongTermDebtTotal, last fiscal year)
Net Debt = -1.14b USD (from netDebt column, last quarter)
Enterprise Value = 19.08b USD (21.54b + Debt 300.0m - CCE 2.77b)
Interest Coverage Ratio = 69.07 (Ebit TTM 1.68b / Interest Expense TTM 24.3m)
FCF Yield = 5.88% (FCF TTM 1.12b / Enterprise Value 19.08b)
FCF Margin = 35.86% (FCF TTM 1.12b / Revenue TTM 3.13b)
Net Margin = 40.65% (Net Income TTM 1.27b / Revenue TTM 3.13b)
Gross Margin = 88.59% ((Revenue TTM 3.13b - Cost of Revenue TTM 356.9m) / Revenue TTM)
Gross Margin QoQ = 87.38% (prev 89.03%)
Tobins Q-Ratio = 2.60 (Enterprise Value 19.08b / Total Assets 7.35b)
Interest Expense / Debt = 1.0% (Interest Expense 3.00m / Debt 300.0m)
Taxrate = 22.67% (99.3m / 438.0m)
NOPAT = 1.30b (EBIT 1.68b * (1 - 22.67%))
Current Ratio = 6.40 (Total Current Assets 3.49b / Total Current Liabilities 546.3m)
Debt / Equity = 0.05 (Debt 300.0m / totalStockholderEquity, last quarter 6.59b)
Debt / EBITDA = -0.67 (Net Debt -1.14b / EBITDA 1.71b)
Debt / FCF = -1.01 (Net Debt -1.14b / FCF TTM 1.12b)
Total Stockholder Equity = 6.75b (last 4 quarters mean from totalStockholderEquity)
RoA = 17.30% (Net Income 1.27b / Total Assets 7.35b)
RoE = 18.83% (Net Income TTM 1.27b / Total Stockholder Equity 6.75b)
RoCE = 24.67% (EBIT 1.68b / Capital Employed (Total Assets 7.35b - Current Liab 546.3m))
RoIC = 18.87% (NOPAT 1.30b / Invested Capital 6.88b)
WACC = 7.48% (E(21.54b)/V(21.84b) * Re(7.57%) + D(300.0m)/V(21.84b) * Rd(1.0%) * (1-Tc(0.23)))
Discount Rate = 7.57% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -2.54%
[DCF Debug] Terminal Value 80.88% ; FCFE base≈1.03b ; Y1≈1.22b ; Y5≈1.90b
Fair Price DCF = 757.2 (DCF Value 32.60b / Shares Outstanding 43.1m; 5y FCF grow 19.75% → 3.0% )
EPS Correlation: 74.34 | EPS CAGR: 34.59% | SUE: -0.34 | # QB: 0
Revenue Correlation: 98.07 | Revenue CAGR: 19.09% | SUE: -0.55 | # QB: 0
EPS next Quarter (2026-03-31): EPS=7.02 | Chg30d=-0.265 | Revisions Net=+1 | Analysts=4
EPS next Year (2026-12-31): EPS=28.49 | Chg30d=+0.447 | Revisions Net=+5 | Growth EPS=+5.1% | Growth Revenue=+5.8%
Additional Sources for UTHR Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle